Mixed Lignan-Neolignans from Tarenna attenuata

Xian-Wen Yang,^{†,‡} Pei-Ji Zhao,[†] Yan-Lin Ma,[§] Hai-Tao Xiao,[⊥] Yi-Qing Zuo,[§] Hong-Ping He,[†] Ling Li,[§] and Xiao-Jiang Hao^{*,†}

State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650204, People's Republic of China, Department of Natural Product Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, People's Republic of China, Yunnan Pharmacological Laboratories of Natural Products, Kunming Medical College, Kunming 650031, People's Republic of China, and School of Pharmacy, Guiyang Medical College, Guiyang 550004, People's Republic of China

Received August 10, 2006

Six new mixed lignan-neolignans and 20 known compounds were isolated from the whole plant of *Tarenna attenuata*. By analysis of physical and spectroscopic data, the structures of the new compounds were elucidated as (1R,5R,6R)-6-{4-*O*-[2-(1-(4-hydroxy-3-methoxyphenyl))glycerol]-3,5-dimethoxyphenyl}-3,7-dioxabicyclo[3.3.0]octan-2-one (1), 5"-methoxyhedyotisol A (2), 4"-*O*-(8-guaiacylglycerol)buddlenol A (3), 5"-methoxy-4"-*O*-(8-guaiacylglycerol)buddlenol A (4), 4,6-dimethoxy-5-hydroxy-3-hydroxymethyl-2-(3,4,5-trimethoxyphenyl)-2,3-dihydrobenzofuran (5), and 7-*O*-ethylguaiacylglycerol (6). Compounds 1, 5, 6, and 8 showed potent antioxidant activities against H₂O₂-induced impairment in PC12 cells, and compounds 1, 2, 5, and 7 scavenged DPPH radical strongly with IC₅₀ values of 72, 87, 45, and 55 μ M, respectively.

Tarenna attenuata (Voigt) Hutchins, a shrub or small tree of the Rubiaceae family, is widely distributed in India, Vietnam, Cambodia, and China.¹ It is used as an antinociceptive and antipyretic by native communities in the traditional medicinal system of Guangxi Province, People's Republic of China.² In our recent search for bioactive compounds from the crude extract of medicinal plants, we found that the ethanol extract of *T. attenuata* exhibited potent antioxidant effects against H_2O_2 -induced impairment in PC12 cells. Previous studies have reported the isolation of 10 iridoids, but none of them showed antioxidant activities.³ This paper deals with the isolation and structure elucidation of six new and 20 known lignan constituents, as well as the antioxidant activities of some.

Results and Discussion

The EtOAc-soluble fraction of the EtOH extract of the whole plants of T. attenuata was subjected to column chromatography on silica gel, RP-18, and Sephadex LH-20, as well as preparative TLC to afford six new (1-6) and 20 known lignans: hedyotisol A (7),^{4,5} buddlenol A (8),^{5,6} guaiacylglycerol (9),⁷ buddlenols C-E,^{5,6} fiscusesquilignan A,^{5,8} (+)-pinoresinol,⁹ (+)-syringaresinol,⁹ 2,3dihydro-2-(4-hydroxy-3-methoxyphenyl)-3-hydroxymethyl-5-(2formylvinyl)-7-hydroxybenzofuran,¹⁰ balanophonin,^{11,12} glycosmisic acid,^{13,14} ficusal,⁸ ω-hydroxypropioguaiacone,¹⁵ dihydrocubebin,¹⁶ 4.4'.7-trihydroxy-3.3'-dimethoxy-9.9'-epoxylignan,^{17,18} isoferulaldehvde.¹⁹ sinapaldehvde.²⁰ cinnamic acid.²¹ and ferulic acid.²² Compound 1 had a molecular formula of $C_{24}H_{28}O_{10}$ from the positive HRESIMS (found 499.1571, calcd for C₂₄H₂₈O₁₀Na, 499.1580). Its IR spectrum showed absorptions of hydroxy (3439 cm⁻¹), ester carbonyl (1767 cm⁻¹), and aromatic moieties (1630, 1550, and 1462 cm⁻¹). The ¹H NMR data of **1** (Table 1) indicated the presence of a 1,3,4-trisubstituted benzene moiety [$\delta_{\rm H}$ 6.91 (1H, s, H-2"), 6.77 (1H, d, J = 8.2 Hz, H-5"), 6.75 (1H, d, J = 8.2 Hz, H-6")], a 1,3,4,5-tetrasubstituted benzene ring [($\delta_{\rm H}$ 6.62 (2H, s, H-2',6'], three oxymethines, three oxymethylenes, and two other aliphatic methines. From the ¹H-¹H COSY spectrum (Figure 1), two partial structures, [-OCHCH(OH)CH₂O-] and [-OCHCH-

Table 1. ¹H and ¹³C NMR Data for Compound 1 in CDCl₃ (δ in ppm, *J* in Hz in parentheses)

position	$\delta_{ m C}{}^a$	$\delta_{ ext{H}}{}^{b}$	position	$\delta_{ ext{C}}{}^{a}$	${\delta_{\mathrm{H}}}^b$
1	46.0	3.49 m	1‴	131.1	
2	177.8		2″	108.2	6.96 s
4	70.3	4.41 d (9.5)	3″	144.8	
		4.24 dd (9.5, 3.4)	4‴	146.6	
5	48.6	3.13 m	5″	114.1	6.86 d (8.4)
6	86.0	4.63 d (7.2)	6‴	118.6	6.73 d (8.4)
8	69.6	4.54 dd (9.8, 6.7)	7″	72.5	4.99 d (3.9)
		4.38 dd (9.8, 1.5)	8″	87.1	4.13 dd (6.6,
					3.9)
1'	135.5		9″	60.5	3.92 m
2',6'	102.8	6.62 s			3.51 m
3',5'	153.6		3',5'-OMe	56.3	3.90 s
4'	134.7		3"-OMe	56.0	3.90 s

^a Recorded at 125 MHz. ^bRecorded at 500 MHz.

(CH₂)CHCH₂O-], are feasible. In the HMBC spectrum (Figure 1), the correlations of H₂-4 ($\delta_{\rm H}$ 4.41 and 4.24, each 1H) and H-1 $(\delta_{\rm H} 3.49)$ to C-2 $(\delta_{\rm C} 177.8)$, H-6 $(\delta_{\rm H} 4.63)$ to C-2',6' $(\delta_{\rm C} 102.8)$, and H-2',6' ($\delta_{\rm H}$ 6.62) to C-6 ($\delta_{\rm C}$ 86.0) suggested compound 1 could be a 3,7-dioxabicyclo[3.3.0]octane-type lignan. Moreover, the correlations of H-7" ($\delta_{\rm H}$ 4.99) to C-2" ($\delta_{\rm C}$ 108.2) and H-6" ($\delta_{\rm H}$ 6.73) to C-7" ($\delta_{\rm C}$ 72.5) indicated the presence of a guaiacylglycerol moiety. Compared to guaiacylglycerol (9), C-8" in compound 1 was downshifted from $\delta_{\rm C}$ 75.6 to 87.1 ppm, which implied the connection of C-8" to C-4'. Since there was no correlation between H-8" and C-4' in the HMBC spectrum obtained using a standard Bruker HMBC pulse program, tandem MS was adopted to confirm the structure. According to the MS/MS spectrum, the parent ion at m/z 499.4 lost a guaiacylglycerol group to give the daughter ion at m/z 302.1, thus establishing the connection of C-8" of the guaiacylglycerol moiety to C-4'. The absolute configuration at C-6 was considered to be R, as the coupling constant of H-6 was 7.2 Hz.²³ In the ROESY spectrum (Figure 1), the correlations of H-6/ H-4a, H-4a/H-1, and H-1/H-5 suggested that C-1 and C-5 were both R configured. Therefore, compound 1 was defined as (1*R*,5*R*,6*R*)-6-{4-*O*-[2-(1-(4-hydroxyphenyl-3-methoxy))glycerol]-3,5-dimethoxyphenyl}-3,7-dioxabicyclo[3.3.0]octan-2-one.

Compound **2** exhibited an $[M + Na]^+$ ion peak at m/z 863.3119 in the positive HRESIMS, corresponding to the molecular formula $C_{43}H_{52}O_{17}$. The IR spectrum displayed absorption bands for hydroxy (3441 cm⁻¹) and aromatic moieties (1618, 1505, and 1462 cm⁻¹). Its ¹H and ¹³C NMR spectroscopic data were very closely related

10.1021/np0603931 CCC: \$37.00 © 2007 American Chemical Society and American Society of Pharmacognosy Published on Web 03/08/2007

^{*} To whom correspondence should be addressed. Tel: +86-871-5223263. Fax: +86-871-5219684. E-mail: haoxj@mail.kib.ac.cn.

[†] Kunming Institute of Botany.

[‡] Second Military Medical University.

[§] Kunming Medical College.

[⊥] Guiyang Medical College.



Figure 1. Key HMBC, $^{1}H^{-1}H$ COSY, and ROESY correlations of 1.

Chart 1



to those of compound **7** (Table 2). Comparison of the ¹³C NMR spectrum of these two compounds showed that compound **2** had an additional resonance at $\delta_{\rm C}$ 104.4. In the HMBC spectrum, H-7" (δ 4.85) correlated with this resonance. Therefore, the only difference between these two compounds is that H-5" in compound **7** was substituted by a methoxy group in compound **2**. Further confirmation was found in the tandem MS spectrum of compound **2**, indicating that the parent ion at m/z 863.4 afforded daughter ions with loss of a guaiacylglycerol moiety at m/z 667.2, a syringoylglycerol moieties at m/z 439.2. Compound **2** was, therefore, defined as 5"-methoxyhedyotisol A.

Compound 3 was assigned the molecular formula C41H46O15 from the positive HRESIMS. Its IR spectrum revealed absorption bands for hydroxy (3443 cm⁻¹) and aromatic moieties (1630, 1595, and 1464 cm⁻¹). The ¹H and ¹³C NMR spectroscopic data were similar to those of compound 8, except for the presence of a guaiacylglycerol [$\delta_{\rm H}$ 7.00 (H, s, H-2^{'''}), 6.83 (1H, m, H-6^{'''}), 6.71 (1H, m, H-5^{'''}), 4.88 (1H, m, H-7^{'''}), 4.25 (1H, m, H-8^{'''}); δ_C 120.6 (CH, C-6""), 115.6 (CH, C-5""), 111.6 (CH, C-2""), 87.0 (CH, C-8""), 73.9 (CH, C-7"'), 61.8 (CH₂, C-9"'), 56.4 (CH₃, 3"'-OMe)]. Compared to 8 and 9, C-8^{'''} was downshifted from $\delta_{\rm C}$ 75.6 to 87.0 and C-4" was downshifted from $\delta_{\rm C}$ 146.0 to 146.8, thus establishing the connection of C-8"" to C-4" via an ether linkage. This assumption was further confirmed by a tandem MS spectrum and an HMBC correlation of H-8"" ($\delta_{\rm H}$ 4.25, m) to C-4" ($\delta_{\rm C}$ 146.8). Therefore compound 3 was defined as 4"-O-(8-guaiacylglycerol)buddlenol A.

Compound **4** had the molecular formula $C_{42}H_{48}O_{16}$ from the positive HRESIMS at m/z 831.2827. Its UV, IR, and ¹H and ¹³C NMR spectroscopic data were similar to those of compound **3** except for the presence of a syringoylglycerol group and a

Table 2. ¹H and ¹³C NMR Data for Compounds **2** and **7** in CD₃OD (δ in ppm, *J* in Hz in parentheses)

		2	7		
position	$\delta_{ ext{C}}{}^{a}$	$\delta_{\rm H}{}^{b}$	$\delta_{ ext{C}}{}^{a}$	$\delta_{ ext{H}}{}^{b}$	
1,1'	132.7		135.7		
2,6,2',6'	103.5	6.67 s	104.1	6.68 s	
3.5.3'.5'	153.8		154.4		
4,4'	138.3		139.0		
7,7'	86.5	4.74^{f}	87.2	4.74 brs ^f	
8,8'	55.0	3.11 brs	55.6	3.11 brs	
9,9'	72.4	4.27 m ^c ,	73.0	4.28 m ^c ,	
		3.91 m ^d		3.92 m ^d	
1‴	133.1		133.8		
2"	104.4	6.62 s	111.2	6.95 s	
3″	153.4		148.6		
4‴	130.1		146.8		
5″	153.4		115.6	6.72 d (7.8)	
6″	104.4	6.62 s	120.6	6.75 d (7.8)	
7″	73.4	4.85 brsf	74.0	4.86 m ^f	
8″	86.5	4.28 m ^c	87.1	4.26 m ^c	
9″	60.8	3.90 m ^d ,	61.3	3.91 m ^d ,	
		3.59 m		3.60 d (11.9)	
1‴	132.1		133.8		
2‴	110.6	6.94 s	111.2	6.95 s	
3‴	148.2		148.6		
4‴	146.2		146.8		
5‴	115.0	6.73 m ^e	115.6	6.72 d (7.8)	
6‴	120.0	6.74 m ^e	120.6	6.75 d (7.8)	
7‴	73.6	4.84 brs ^f	74.0	4.86 m ^f	
8‴	86.5	4.28 m ^c	87.1	4.26 m ^c	
9‴	60.8	3.90 m ^d ,	61.3	3.91 m ^d ,	
		3.59 m		3.60 d (11.9)	
3,5,3',5'-OMe	56.0	3.82 s	56.6	3.85 s	
3"-OMe	56.0	3.82 s	56.3	3.83 s	
5"-OMe	56.0	3.82 s			
3‴-OMe	55.6	3.80 s	56.3	3.83 s	

^{*a*} Spectra were measured at 100 MHz. ^{*b*}Spectra were measured at 500 MHz. ^{*c.d.e.*}Signals in the same column were overlapped. /Hidden in the D₂O signals.

Table 3. ¹H and ¹³C NMR Data for Compounds **3**, **4**, and **8** in CD_3OD (δ in ppm, *J* in Hz in parentheses)

	3		4		8		
position	$\delta_{ ext{C}}{}^{a}$	$\delta_{ ext{H}}{}^{b}$	$\delta_{ ext{C}}{}^{a}$	$\delta_{ ext{H}}{}^{b}$	$\delta_{ ext{C}}{}^{a}$	$\delta_{ ext{H}}{}^{b}$	
1	129.9		129.9s		129.9		
2	114.2	7.23 s	114.2d	7.23 s	114.5	7.20 s	
3	146.0		145.9 s		146.0		
4	152.7		152.6s		152.8		
5	130.8		130.0s		130.9		
6	120.0	7.26 s	120.0d	7.26 s	120.0	7.24 s	
7	156.1	7.61 d (15.7)	156.0d	7.60 d (15.7)	155.9	7.88 d (15.6)	
8	127.2	6.67 m	127.2d	6.66 m	127.3	6.67 m	
9	196.3	9.58 d (7.8)	196.2d	9.57 d (7.8)	196.1	9.50 d (7.8)	
1'	138.9		139.0s		132.8		
2',6'	103.8	6.68 s	103.8d	6.68 s	104.1	6.68 s	
3′,5′	154.3		154.6s		154.7		
4'	136.4		136.4s		138.8		
7'	89.6	5.64 brs	89.6d	5.64 m	89.6	5.63 m	
8′	54.9	3.50 m	55.0d	3.54 m	55.0	3.52 m	
9'	64.6	3.88 m ^d	64.7t	3.87 m ^d	64.7	3.87 m ^d	
		3.81 m		3.80 m		3.81 m	
1‴	133.7		139.0s		131.0		
2″	112.0	7.00 s	105.3d	6.70 m	111.4	6.94 s	
3″	148.6		154.1s		149.2		
4‴	146.8		136.4s		146.0		
5″	115.8	6.71 d (8.0)	154.1s		116.2	6.70 d (8.0)	
6‴	120.6	6.83 d (8.0)	105.3d	6.70 m	120.8	6.82 d (8.0)	
7″	73.9	4.88 m ^e	74.0d	4.94 m ^e	74.3	4.88 m ^e	
8″	87.0	4.25 m	87.5d	4.18 brs	87.2	4.25 m	
9″	61.8	3.86 m ^d	61.3t	3.86 m ^d	61.8	3.86 m^d	
		3.45 m		3.60 m		3.45 m	
1‴	133.7		133.8s				
2‴	111.6	7.00 s	111.2d	6.95 s			
3‴	148.8		148.7s				
4‴	146.6		146.8s				
5‴	115.6	6.71 d (8.0)	115.7d	6.72 m^{c}			
6‴	120.6	6.83 d (8.0)	120.5d	6.73 m ^c			
7‴	73.9	4.88 m ^e	73.9d	4.93 m ^e			
8′′′	87.0	4.25 m	86.8d	4.28 m			
9‴	61.8	3.86 m	61.6t	3.86 m ^{<i>d</i>}			
		3.45 m		3.54 m			
3-OMe	57.0	3.92 s	57.0	3.92 s	57.0	3.90 s	
3',5'-OMe	56.7	3.78 s	56.7	3.78 s	56.7	3.78 s	
3''-OMe	56.6	3.80 s	56.6	3.80 s	56.4	3.80 s	
5''-OMe			56.6	3.80 s			
3'''-OMe	56.4	3.79 s	56.4	3.79 s			

^{*a*} Recorded in CD₃OD (100 MHz). ^{*b*}Recorded in CD₃OD (500 MHz). ^{*cd*}Signals in the same column were overlapped. ^{*e*}Hidden in the D₂O signals.

guaiacylglycerol group instead of two guaiacylglycerol groups in 4. Since there was no correlation of H-8" and H-8" in the HMBC NMR spectrum, the tandem MS method was used to determine the structure of compound 4. In the MS/MS spectrum, the parent ion at m/z 831.3 lost a guaiacylglycerol group to give the daughter ion at m/z 634.1, which indicated that the syringoylglycerol group was connected to C-4', while the guaiacylglycerol moiety was

attached to C-4". On the basis of the above evidence, compound **4** was determined as 5"-methoxy-4"-O-(8-guaiacylglycerol)buddlenol A.

Compound 5 was assigned the molecular formula C₂₀H₂₄O₈ from the positive HRESIMS at m/z 415.1362. Its IR showed absorption bands for hydroxy (3441 cm⁻¹) and aromatic moieties (1619, 1517, and 1465 cm⁻¹). The ¹H NMR spectroscopic data (Table 4) indicated the presence of a benzofuran-type lignan moiety [$\delta_{\rm H}$ 5.55 (1H, d, J = 4.4 Hz, H-7), 3.52 (1H, dd, J = 8.3, 4.4 Hz, H-8), 3.93 (1H, dd, J = 10.8, 3.8 Hz, H-9a), 3.66 (1H, dd, J = 10.8, 8.3 Hz, H-9b)], which was supported by resonances in the ¹³C NMR spectrum [δ_C 89.0 (CH, C-7), 54.6 (CH, C-8), 64.1 (CH₂, C-9)]. Furthermore, its 1D NMR showed the presence of a 3,4,5trimethoxylphenyl group [$\delta_{\rm H}$ 6.62 (2H, s, H-2,6); $\delta_{\rm C}$ 104.0 (CH, C-2,6), 61.5 (CH₃, 4-OMe), 56.8 (CH₃, 3,5-OMe)]. According to the HMBC spectrum, the above fragments were connected as shown in Figure 2. Since the coupling constant of H-7 was 4.4 Hz, the relative configuration of C-7 and C-8 was regarded as cis.²⁴ This configuration is opposite of that of the same protons in balanophonin,¹¹ for which J values (trans) are 7.0 Hz. Therefore compound 5 was determined as 4,6-dimethoxy-5-hydroxy-3-hydroxymethyl-2-(3,4,5-trimethoxyphenyl)-2,3-dihydrobenzofuran. However, a paucity of material prevented determination of the absolute configuration.

Compound 6 gave the molecular formula $C_{12}H_{18}O_5$ from the positive HRESIMS at m/z 265.1050. Its ¹H and ¹³C NMR spectroscopic data (Table 4) gave two fragments, including a guaiacylglycerol group [$\delta_{\rm H}$ 6.91 (1H, s, H-2), 6.77 (1H, d, J = 8.2Hz, H-5), 6.75 (1H, d, J = 8.2 Hz, H-6); $\delta_{\rm C}$ 121.3 (CH, C-6), 115.91 (CH, C-5), 111.7 (CH, C-2), 83.6 (CH, C-7), 77.0 (CH, C-8), 63.9 (CH₂, C-9), 56.3 (CH₃, 3-OMe)] and an ethoxy moiety [$\delta_{\rm H}$ 3.39 (1H, d, J = 7.0 Hz, H-1'a), 3.34 (1H, d, J = 7.0 Hz, H-1'b) 1.16 (3H, t, J = 7.0 Hz, 2'-Me); $\delta_{\rm C}$ 65.2 (CH₂, C-1'), 15.5 (CH₃, 2'-Me)]. Compared to guaicylglycerol (9), C-7 in compound 6 was downshifted from $\delta_{\rm C}$ 75.6 to 83.6, which established the connection of the ethoxy at C-7 of the guaicylglycerol. This was confirmed by the HMBC correlation of H-7 ($\delta_{\rm H}$ 4.19, d, J = 6.6 Hz) to C-1' ($\delta_{\rm C}$ 65.2). Therefore, compound **6** was elucidated as 7-O-ethylguaiacylglycerol. It has been reported that in the cases of syringoylglycerols and guaiacylglycerol derivatives, the coupling constant between H-7 and H-8 was about 5 Hz for the erythro isomer and 7 Hz for the *threo* isomer.²⁵ Thus, compound **6** was considered to be the *threo* isomer. To confirm whether compound **6** is artifactual because 95% EtOH was used as the solvent for extraction, another supply of the plant was obtained and extracted with MeOH and EtOH, respectively. By LC-MS, compound 6 was detected in the

Table 4.	¹ H and ¹³ C NMF	R Data for Co	ompounds 5, 6	, and 9 in	CD ₃ OD (δ i	n ppm, J ir	n Hz in	parentheses
----------	--	---------------	---------------	-------------------	-------------------------	-------------	---------	-------------

	5			6	9	
position	$\delta_{ m C}{}^a$	$\delta_{ ext{H}^c}$	$\delta_{ m C}{}^b$	$\delta_{ ext{H}^{c}}$	$\delta_{\mathrm{C}}{}^{b}$	$\delta_{ ext{H}}{}^{c}$
1	134.1		132.1		134.0	
2	104.0	6.62 s	111.7	6.91 s	111.6	6.96 s
3	149.4		149.0		149.9	
4	136.7		147.4		148.3	
5	149.4		115.9	6.77 d (8.2)	116.2	6.78 d (7.9)
6	104.0	6.62 s	121.3	6.75 d (8.2)	120.7	6.73 d (7.9)
7	89.0	5.55 d (4.4)	83.6	4.19 d (6.6)	77.6	4.48 d (3.4)
8	54.6	3.52 dd (8.3, 4.4)	77.0	3.65 m	75.6	3.64 m
9	64.1	3.93 dd (10.8, 3.8) 3.66 dd (10.8, 8.3)	63.9	3.43 dd (11.1, 3.1) 3.33 m	64.3	3.45 m
1'	136.8	5.00 uu (10.0, 0.5)	65.2	3 39 d (7 0) 3 34 d (7 0)		
2'	152.5		15.5	1 16 t (7 0)		
3'	110.8		1010			
4'	159.3					
5'	91.5	6.35 s				
6'	157.2					
3-OMe	56.8	3.80 s	56.3	3.84 s	56.4	3.84 s
4-OMe	61.5	3.73 s				
5-OMe	56.8	3.80 s				
2'-OMe	61.1	3.89 s				
6'-OMe	56.8	3.81 s				

^a Recorded at 100 MHz. ^bRecorded at 125 MHz. ^cRecorded at 500 MHz.

Table 5. Antioxidant Effects of Compounds 1-8 by MTT and DPPH Assays

group	0.4	2.0	10.0	50.0	$IC_{50} (\mu M)^e$
control	100***				
model ^c	51.5 ± 2.7				
edaravone ^d	$55.5 \pm \pm 1.4*$	53.1 ± 3.9	47.8 ± 2.2	25.6 ± 2.3	27
compound 1	$59.3 \pm 2.8 * *$	$61.8 \pm 2.5^{**}$	$59.4 \pm 1.9^{**}$	45.7 ± 4.4	72
compound 2	51.9 ± 2.9	54.3 ± 3.9	54.7 ± 2.6	54.1 ± 3.6	87
compound 3	52.8 ± 4.0	47.9 ± 8.9	64.4 ± 18.7	55.9 ± 6.4	201
compound 4	50.3 ± 5.5	54.7 ± 4.2	$55.2 \pm 1.6^{*}$	51.0 ± 5.5	127
compound 5	$61.4 \pm 3.1^{**}$	$58.0 \pm 2.7 **$	$58.2 \pm 1.5^{**}$	55.0 ± 3.0	45
compound 6	54.1 ± 1.9	54.9 ± 1.8	$56.8 \pm 2.9^{*}$	$57.3 \pm 2.5^{*}$	132
compound 7	52.2 ± 4.7	53.2 ± 3.5	54.3 ± 2.0	55.3 ± 5.1	55
compound 8	56.9 ± 6.6	568 ± 52	$62.6 \pm 8.5*$	$64.8 \pm 9.7*$	147

^{*a*} Effects of compounds 1–8 against H₂O₂-induced impairment in PC12 cells. ^{*b*}*n* = 5, $X \pm$ SD. **P* < 0.05, ***P* < 0.01, ****P* < 0.001 vs model. ^{*c*}Negative control. ^{*d*}Positive control. ^{*e*}Radical-scavenging activities of compounds 1–8 against DPPH.



Figure 2. Key HMBC correlations of compound 5.

EtOH extract (2.0 mg/mL), while it was not detected in the MeOH extract (2.0 mg/mL). Thus, compound 6 was established unequivocally as an artifact of extraction.

The antioxidant effects of compounds 1-8 were evaluated by both MTT and DPPH assays (Table 5). Compounds 1, 5, 6, and 8 showed potent activities against H₂O₂-induced impairment in PC12 cells within the concentration range tested (0.4 to 50 μ M), whereas compounds 1, 2, 5, and 7 scavenged DPPH radical strongly, with IC₅₀ values of 74.5, 87.1, 45.4, and 55.0 μ M, respectively.

T. attenuata has been used as an antinociceptive by native communities in the traditional medicinal system of Guangxi Province, People's Republic of China. Recent studies showed that the antinociceptive activity might be closely related to the free radical-scavenging effect.^{26,27} Thus the result in our current study provides a possible mechanism to account for its use as a traditional antinociceptive.

Experimental Section

General Experimental Procedures. Optical rotations were measured with a Horiba SEPA-300 polarimeter or JASCO DIP-370 digital polarimeter. UV spectra were obtained using a Shimadzu UV-2401PC spectrometer. IR spectra were recorded on a Bio-Rad FTS-135 spectrometer with KBr pellets. ¹H and ¹³C NMR experiments were performed on a Bruker AM-400 or DRX-500 NMR spectrometer with TMS as internal standard. LC-MS/MS and ESIMS were measured on a Waters 2695 HPLC-Thermo Finnigan LCQ Advantage ion trap mass spectrometer. EIMS and HRESIMS were taken on a VG Auto Spec 3000 spectrometer. Column chromatography was performed with silica gel (200-300 mesh; Qingdao Marine Chemical, Inc., Qingdao, People's Republic of China), silica gel H (10-40 µm; Qingdao), Sephadex LH-20 (40-70 µm; Amersham Pharmacia Biotech AB, Uppsala, Sweden), and Lichroprep RP-18 gel (40-63 µm; Merck, Darmstadt, Germany). Zones of preparative TLC plates (1.0-1.5 mm; Qingdao) and TLC plates (0.20-0.25 mm; Qingdao) were visualized under UV light or by spraying with 10% H₂SO₄ in 95% EtOH, followed by heating.

Plant Material. The whole plant of *T. attenuata*, collected in Xishuangbanna of Yunnan Province, People's Republic of China, in October 2004, was identified by Prof. Jing-Yun Cui, Xishuangbanna Tropical Botanical Garden, Chinese Academy of Sciences. A voucher specimen (BN163) was deposited in Kunming Institute of Botany, Chinese Academy of Sciences.

Extraction and Isolation. The dried and powdered (17 kg) sample of *T. attenuata* was extracted with 95% EtOH (16 L) under reflux for 3×4 h. The extract was concentrated to dryness under reduced pressure. The residue was suspended in H₂O and partitioned, sequentially, with petroleum ether, EtOAc, and *n*-BuOH. The EtOAc extract

(61 g) was separated into eight fractions (F_1-F_8) by column chromatography on silica gel using a CHCl3-MeOH gradient. Fraction F1 was further separated by column chromatography on silica gel with petroleum ether-EtOAc (20:1) to give cinnamic acid (18 mg). Fraction F2 was separated using reversed-phase MPLC by a gradient of H2O-MeOH and preparative TLC with EtOAc-MeOH (100:1) to give 7 (32 mg) and 8 (3 mg). Repeated column chromatography of fraction F₃ over silica gel (petroleum ether-EtOAc, 1:1; CHCl₃-MeOH, 50: 1) gave 1 (1.1 mg), 2 (3.7 mg), 3 (6.1 mg), and 4 (6.6 mg). Fraction F4 was subjected to column chromatography on silical gel (EtOAc-MeOH, 50:1) and Sephadex LH-20 (CHCl₃-MeOH, 1:1) to give 6 (6 mg), buddlenol D (15 mg), and balanophonin (8 mg). Fraction F_5 was divided into six subfractions (F_{5.1}-F_{5.6}) by column chromatography over silica gel (EtOAc-MeOH, 50:1). Subfraction F_{5.2} was then chromatographed on a silical gel column (CHCl3-MeOH, 40:1) to give 9 (23 mg), 2,3-dihydro-2-(4-hydroxy-3-methoxyphenyl)-3-hydroxymethyl-5-(2-formylvinyl)-7-hydroxybenzofuran (3 mg), and glycosmisic acid (9 mg). Repeated chromatography of subfraction F_{5.4} on silica gel eluted with CHCl₃–MeOH (30:1) afforded ω -hydroxypropioguaiacone (4 mg), 4,4',7-trihydroxy-3,3'-dimethoxy-9,9'-epoxylignan (8 mg), isoferulaldehyde (11 mg), and sinapaldehyde (10 mg). Fraction F₆ was chromatographed on a silica gel column eluting with EtOAc-MeOH (20:1) to give seven subfractions ($F_{6.1}-F_{6.7}$). Subfraction $F_{6.2}$ was further chromatographed over a silica gel column (CHCl₃-MeOH, 10:1) to give 5 (0.6 mg) and buddlenol C (5 mg). Repeated chromatography of subfraction F_{6.3} over silical gel (CHCl₃-MeOH, 10:1) afforded buddlenol E (2 mg), fiscusesquilignan A (1 mg), (+)-pinoresinol (2 mg), and (+)-syringaresinol (20 mg). Subfraction F_{6.5} was separated by chromatography eluting with EtOAc-MeOH (8:1) and Sephadex LH-20 eluting with MeOH to give ficusal (6 mg), dihydrocubebin (9 mg), and ferulic acid (34 mg).

(1*R*,5*R*,6*R*)-6-{4-*O*-[2-(1-(4-Hydroxyphenyl-3-methoxy))glycerol]-3,5-dimethoxyphenyl}-3,7-dioxabicyclo[3.3.0]octan-2-one (1): amorphous powder; $[\alpha]_{D}^{2D}$ -9.4 (*c* 0.60, MeOH); UV (MeOH) λ_{max} (log ϵ) 280 (3.81), 344 (3.17) nm; IR (KBr) ν_{max} 3439, 2932, 1767, 1630, 1550, 1462, 1425, 1382, 1333, 1273, 1221, 1125, 1033, 772 cm⁻¹; ¹H and ¹³C NMR spectroscopic data, see Table 1; ESIMS (positive) *m*/*z* 499 [M + Na]⁺; HRESIMS (positive) *m*/*z* 499.1571 [M + Na]⁺ (calcd for C₂₄H₂₈O₁₀Na, 499.1580).

5"-Methoxyhedyotisol A (2): amorphous powder; $[\alpha]_D^{27}$ +6.5 (*c* 0.21, MeOH); UV (MeOH) λ_{max} (log ϵ) 205 (4.92), 280 (3.69), 357 (3.21) nm; IR (KBr) ν_{max} 3441, 2937, 1618, 1505, 1462, 1423, 1369, 1354, 1226, 1124, 1033, 774, 766 cm⁻¹; ¹H and ¹³C NMR spectroscopic data, see Table 2; ESIMS (positive) m/z 863 [M + Na]⁺; HRESIMS (positive) m/z 863.3119 [M + Na]⁺ (calcd for C₄₃H₅₂O₁₇Na, 863.3102).

4"-**O**-(**8**-Guaiacylglycerol)buddlenol A (3): amorphous powder; $[\alpha]_{27}^{27}$ +5.4 (*c* 0.34, MeOH); UV (MeOH) λ_{max} (log ϵ) 204 (4.84), 281 (3.88), 335 (3.90) nm; IR (KBr) ν_{max} 3443, 2936, 1630, 1595, 1511, 1464, 1424, 1383, 1350, 1270, 1222, 1127, 1032, 822, 767 cm⁻¹; ¹H and ¹³C NMR spectroscopic data, see Table 3; ESIMS (positive) *m/z* 801 [M + Na]⁺; HRESIMS (positive) *m/z* 801.2753 [M + Na]⁺ (calcd for C₄₁H₄₆O₁₅Na, 801.2734).

5"-**Methoxy-4**"-**O**-(**8**-guaiacylglycerol)buddlenol A (4): amorphous powder; $[\alpha]_D^{27}$ +5.9 (*c* 0.38, MeOH); UV (MeOH) λ_{max} (log ϵ) 205 (4.78), 279 (3.83), 334 (3.72) nm; IR (KBr) ν_{max} 3442, 2940, 2843, 1595, 1503, 1463, 1423, 1384, 1352, 1272, 1224, 1126, 1032, 831,

766 cm⁻¹; ¹H and ¹³C NMR spectroscopic data, see Table 3; ESIMS (positive) m/z 831 [M + Na]⁺; HRESIMS (positive) m/z 831.2827 [M + Na]⁺ (calcd for C₄₂H₄₈O₁₆Na, 831.2840).

4,6-Dimethoxy-5-hydroxy-3-hydroxymethyl-2-(3,4,5-trimethoxyphen-yl)-2,3-dihydrobenzofuran (5): amorphous powder; $[\alpha]_D^{19}$ +7.8 (*c* 0.35, MeOH); UV (MeOH) λ_{max} (log ϵ) 207 (4.76), 282 (3.67), 371 (3.02) nm; IR (KBr) ν_{max} 3441, 2933, 1619, 1517, 1465, 1429, 1372, 1275, 1201, 1167, 1118, 1033, 771 cm⁻¹; ¹H and ¹³C NMR spectroscopic data, see Table 4; ESIMS (positive) m/z 415 [M + Na]⁺, 807 [2M + Na]⁺; HRESIMS (positive) m/z 415.1362 [M + Na]⁺ (calcd for C₂₀H₂₄O₈Na, 415.1368).

7-O-Ethylguaiacylglycerol (6): amorphous powder; $[\alpha]_D^{27} + 11.2$ (*c* 0.27, MeOH); UV (MeOH) λ_{max} (log ϵ) 204 (4.17), 229 (3.49), 280 (3.06) nm; IR (KBr) ν_{max} 3421, 2929, 1631, 1612, 1518, 1454, 1432, 1372, 1356, 1279, 1156, 1122, 1094, 1035, 853, 773 cm⁻¹; ¹H and ¹³C NMR spectroscopic data, see Table 4; ESIMS (positive) *m/z* 265 [M + Na]⁺, 506 [2M + Na]⁺; HRESIMS (positive) *m/z* 265.1050 [M + Na]⁺ (calcd for C₁₂H₁₈O₅Na, 265.1051).

Antioxidant Assay against H₂O₂-Induced Impairment in PC12 Cells. PC12 cells were obtained from Kunming Institute of Zoology, Chinese Academy of Sciences, and maintained in a water-saturated atmosphere of 5% CO2 at 37 °C. Cells were seeded into 96-well plates in RPMI 1640 medium (Invitrogen corporation, Grand Isband, NY) with 10% characterized newborn bovine serum (Lanzhou National Hyclone Bio-engineering Co. Ltd., Lanzhou, People's Republic of China). Experiments were carried out 24 h after cells were seeded according to the reported protocol.²⁸ Different concentrations of these eight compounds and freshly prepared H₂O₂ (with final concentration of 0.2 mM) in phosphate-buffered saline (PBS) were added to continue incubation for 1 h. The assay for cell viability was evaluated by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma] reduction.²⁹ Briefly, MTT solution (0.5 mg/mL) in PBS was added and the incubation continued for 4 h. Finally, a 100 µL solution containing 5% i-BuOH, 10% SDS (Sigma), and 0.004% HCl was added. The mixtures were kept overnight, and the index of cell viability (% of control) was calculated by measuring the optical density of the color produced by MTT dye reduction with a microplate reader (Bio-Rad Model 680, Hercules, CA) at 570 nm.

DPPH Radical-Scavenging Activity Assay. The DPPH method³⁰ was used to determine the free radical-scavenging potential of each sample. Each compound (100 μ L in five different concentrations ranging from 0.16 to 100.0 μ M) was added to 100 μ L of DPPH solution (0.1 mM in EtOH). The absorbance was measured with a Spectra MAX 340 microplate reader (Molecular Devices, Menlo Park, CA) at 517 nm after 30 min of reaction at 37 °C. The percentage of radical-scavenging activity (RSA %) was calculated using the following equation: RSA % = [$(A_{\rm C} - A_{\rm S})/A_{\rm C}$] × 100%, where $A_{\rm C}$ is the absorbance of the control and $A_{\rm S}$ is the absorbance of the samples at 517 nm. IC₅₀ values denote the concentration of sample required to scavenge 50% DPPH free radicals.

Acknowledgment. We acknowledge the Department of Instrumental Analysis of our Institute for measuring the optical rotations, UV, IR, NMR, and mass spectra. This research was funded by National Natural Science Foundations of China (No. 30370957) and National Science Foundation of Yunnan Province (No. 2003C0061M).

Supporting Information Available: The ¹H and ¹³C NMR spectra for compound **1**, tandem MS spectra for compounds **1–4**, and LC-MS

spectra for compound **6**. This information is available free of charge via the Internet at http://pubs.acs.org.

References and Notes

- Luo, X. R.; Gao, Y. Z.; Chen, W. Q.; Xu, X. H.; Wu, H. In *Flora Reipublicae Popularis Sinicae*; Wu, Z. Y., Ed.; Science Press: Beijing, 1999; Vol. 71, pp 382–383.
- (2) Board of Health of Revolution Committee in Guangxi Zhuang Autonomous Region. *Guangxi Herbal Selections*; Guangxi People's Publishing House: Nanning, 1974; Vol. 2, pp 1798–1799.
- (3) Yang, X. W.; Ma, Y. L.; He, H. P.; Wang, Y. H.; Di, Y. T.; Zhou, H.; Li, L.; Hao, X. J. J. Nat. Prod. 2006, 69, 971–974.
- (4) Matsuda, S.; Kadota, S.; Tai, T.; Kikuchi, T. Chem. Pharm. Bull. 1984, 32, 5066–5069.
- (5) Houghton, P. J. Phytochemistry 1985, 24, 819-826.
- (6) Cui, Y. L.; Mu, Q.; Hu, C. Q. Nat. Prod. Res. Dev. 2003, 15, 277– 283.
- (7) Comte, G.; Vercauteren, J.; Chulia, A. J.; Allais, D. P.; Delage, C. *Phytochemistry* **1997**, 45, 1679–1682.
- (8) Li, Y. C.; Kuo, Y. H. Chem. Pharm. Bull. 2000, 48, 1862-1865.
- (9) Abe, F.; Yamauchi, T. Phytochemistry 1988, 27, 575-577.
- (10) Miki, K.; Ito, K.; Sasaya, T. Mokuzai Gakkaishi 1979, 25, 665-670.
- (11) Sy, L. K.; Brown, G. D. Phytochemistry 1999, 50, 781-785.
- (12) Haruna, M.; Koube, T.; Ito, K.; Murata, H. Chem. Pharm. Bull. 1982,
- 30, 1525-1527.
 (13) Xiang, Y.; Wang, H.; Wen, Y. Y. J. Trop. Subtrop. Bot. 2002, 10, 69-73.
- (14) Ohta, M.; Higuchi, T.; Iwahara, S. Arch. Microbiol. **1979**, *121*, 23–28.
- (15) Achenbach, H.; Stöcker, M.; Constenla, M. A. *Phytochemistry* **1988**, 27, 1835–1841.
- (16) Dwuma-Badu, D.; Ayim, J. S. K.; Dabra, T. T. J. Nat. Prod. 1975, 38, 343–345.
- (17) Estevez-Braun, A.; Estevez-Reyes, R.; Gonzalez-Perez, J. A.; Gonzalez, A. G. J. Nat. Prod. 1995, 58, 887–892.
- (18) Braum, A. E.; Reyes, R. E.; Perez, J. A. G.; Gonzalez, A. G. J. Nat. Prod. 1995, 58, 887–892.
- (19) Barakat, H. H.; Nawwar, M. A. M.; Buddrusa, J.; Linscheida, M. *Phytochemistry* **1987**, *26*, 1837–1838.
- (20) Lin, J.; Hao, X. J.; Liang, G. Y. Acta Pharm. Sin. 1999, 34, 203– 206.
- (21) Li, S. S.; Tan, N. H.; Zhou, J.; Zhao, S. S. Acta Bot. Yunn. 2001, 23, 115–120.
- (22) Luo, Y. M.; Zhang, J. H.; Pan, J. G.; Yao, S. L.; Huang, H. L.; Zhu, Y.; Li, Q. S. Chin. Pharm. J. 1994, 29, 714–716.
- (23) Duan, H.; Takaishi, Y.; Momota, H.; Ohmoto, Y.; Taki, T. Phytochemistry 2002, 59, 85–90.
- (24) Gongora, L.; Manez, S.; Giner, R. M.; Carmen Recio, M.; Gray, A. I.; Rios, J. L. *Phytochemistry* **2002**, *59*, 857–860.
- (25) Kuima, K.; Otsuka, H.; Ide, T.; Ogimi, C.; Hirata, E.; Takushi, A.; Takeda, Y. *Phytochemistry* **1998**, 48, 669–676.
- (26) Ratnasooriya, W. D.; Deraniyagala, S. A.; Bathige, S. D.; Hettiarachchi, H. D. J. Ethnopharmacol. 2005, 97, 123–128.
- (27) Zhao, Q.; Zhao, Y.; Wang, K. J. Ethnopharmacol. 2006, 106, 408– 413.
- (28) Wang, R.; Zhou, J.; Tang, X. C. Mol. Brain Res. 2002, 107, 1-8.
- (29) Alley, M. C.; Scudiero, D. A.; Monks, A.; Hursey, M. L.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R. *Cancer Res.* **1988**, *48*, 589–601.
- (30) Blois, M. S. Nature 1958, 181, 1199-1200.
- NP0603931